Atria Investments LLC Makes New $391,000 Investment in United Therapeutics Co. (NASDAQ:UTHR)

Share on StockTwits

Atria Investments LLC purchased a new position in United Therapeutics Co. (NASDAQ:UTHR) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 4,273 shares of the biotechnology company’s stock, valued at approximately $391,000.

Other large investors have also bought and sold shares of the company. Pearl River Capital LLC acquired a new position in shares of United Therapeutics in the second quarter worth $32,000. Private Ocean LLC acquired a new position in shares of United Therapeutics during the second quarter worth $34,000. NEXT Financial Group Inc grew its stake in shares of United Therapeutics by 72.7% during the second quarter. NEXT Financial Group Inc now owns 475 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 200 shares in the last quarter. Machina Capital S.A.S. grew its stake in shares of United Therapeutics by 776.4% during the second quarter. Machina Capital S.A.S. now owns 964 shares of the biotechnology company’s stock worth $75,000 after purchasing an additional 854 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of United Therapeutics by 1,023.3% during the second quarter. Tower Research Capital LLC TRC now owns 1,831 shares of the biotechnology company’s stock worth $143,000 after purchasing an additional 1,668 shares in the last quarter. Institutional investors and hedge funds own 94.11% of the company’s stock.

UTHR has been the subject of a number of analyst reports. Wedbush reiterated a “buy” rating and set a $273.00 target price on shares of United Therapeutics in a research note on Thursday, August 1st. Credit Suisse Group upgraded shares of United Therapeutics from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $98.00 to $101.00 in a research note on Monday, July 1st. BidaskClub upgraded shares of United Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, September 18th. Zacks Investment Research downgraded shares of United Therapeutics from a “buy” rating to a “hold” rating and set a $86.00 target price for the company. in a research note on Wednesday, August 14th. Finally, LADENBURG THALM/SH SH upgraded shares of United Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $103.00 to $106.00 in a research note on Thursday, August 1st. One analyst has rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $121.73.

Shares of UTHR opened at $81.89 on Friday. United Therapeutics Co. has a 1-year low of $74.31 and a 1-year high of $128.94. The stock has a market cap of $3.45 billion, a PE ratio of 6.12 and a beta of 0.95. The company has a debt-to-equity ratio of 0.31, a current ratio of 4.62 and a quick ratio of 4.41. The firm has a fifty day moving average price of $81.64 and a 200 day moving average price of $87.74.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $4.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.40 by $2.26. United Therapeutics had a negative net margin of 7.69% and a negative return on equity of 4.54%. The firm had revenue of $373.60 million during the quarter, compared to analysts’ expectations of $331.78 million. As a group, equities analysts expect that United Therapeutics Co. will post -1.96 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Recommended Story: What is an Initial Public Offering (IPO)?

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Atria Investments LLC Makes New Investment in Servicemaster Global Holdings Inc
Atria Investments LLC Makes New Investment in Servicemaster Global Holdings Inc
Atria Investments LLC Purchases 4,845 Shares of Beacon Roofing Supply, Inc.
Atria Investments LLC Purchases 4,845 Shares of Beacon Roofing Supply, Inc.
Atria Investments LLC Acquires 272 Shares of Pool Co.
Atria Investments LLC Acquires 272 Shares of Pool Co.
Atria Investments LLC Makes New Investment in Stamps.com Inc.
Atria Investments LLC Makes New Investment in Stamps.com Inc.
Atria Investments LLC Makes New $391,000 Investment in United Therapeutics Co.
Atria Investments LLC Makes New $391,000 Investment in United Therapeutics Co.
Atria Investments LLC Makes New Investment in 1ST TR EXCHANGE/NYSE ARCA BIOTECHNO
Atria Investments LLC Makes New Investment in 1ST TR EXCHANGE/NYSE ARCA BIOTECHNO


 
© 2006-2019 Zolmax.